Shield Therapeutics announces submission of a New Drug Application (NDA) for Feraccru® with the US Food and Drug Administration (FDA)

Shield Therapeutics plc, today announces that it has received confirmation from the US FDA of its successful submission of an NDA for Feraccru®. For more details please see the press release below.

STX_NDA submission